Bilir, Özlem ArmanDikme, GürcanMalbora, BarışSivis, Zühal ÖnderTüfekçi, ÖzlemBahadır, AyşenurKaraman, SerapVural, SemaBayhan, TuranYaralı, Hüsniye NeşeÇelkan, Tülin TirajeÖzbek, Namık Yaşar2024-01-222024-01-222021-05Bilir, Ö. A. vd. (2021). "Posterior reversible encephalopathy syndrome in childhood hematological/oncological diseases: Multicenter resulte". Journal of Pediatric Hematology/Oncology, 43(4), E462-E465.1077-4114https://journals.lww.com/jpho-online/fulltext/2021/05000/posterior_reversible_encephalopathy_syndrome_in.10.aspxhttps://hdl.handle.net/11452/39209The aim of the study was to analyze the characteristics of posterior reversible encephalopathy syndrome (PRES) cases treated at 10 different institutions in our country. Fifty-eight patients diagnosed with PRES were included in this study. The data of PRES cases from 10 departments of pediatric hematology/oncology were analyzed. The mean age of the patients at the time of diagnosis of PRES was 8.95±3.66 years. Most patients (80.4%) had a primary diagnosis of acute leukemia. Patients received chemotherapy (71.4%) and/or used steroids within 14 days before the diagnosis of PRES (85.7%). Hypertension was found in 83.9% of the patients. Twenty-six patients had infections and 22 of them had febrile neutropenia. The most common electrolyte disorders were hypocalcemia, hypomagnesemia, and hypopotassemia. Six patients had tumor lysis syndrome and 4 had inappropriate antidiuretic hormone syndrome. Magnetic resonance imaging was used for diagnosis in all patients. The most commonly involved regions by magnetic resonance imaging were occipital (58%), parietal (51%), and frontal lobes (45%), respectively. Twenty-five patients required intensive care and 7 patients were intubated. In conclusion, PRES may develop during the follow-up and treatment of hematological diseases. In addition to steroid and intense combined chemotherapies, immunosuppressive agents and hypertension are also factors that may be responsible for PRES.eninfo:eu-repo/semantics/closedAccessChildPresEncephalopathyHematologic diseaseHypertensionNervous-system complicationsAcute lymphoblastic-leukemiaChildrenLeukoencephalopathyManifestationsChemotherapyHematopoietic stem-cellOncologyHematologyPediatricsAdolescentChildFemaleHematologic diseasesHumansHypertensionLeukemiaMagneticResonance imagingMalePosterior leukoencephalopathy syndromeWater-electrolyte imbalanceArticle0006477609000102-s2.0-85105548823E462E46542433060391https://doi.org/10.1097/MPH.0000000000001965OncologyHematologyPediatricsPosterior Reversible Encephalopathy Syndrome; Case Report; Hypertension EncephalopathyAnticonvulsive agentAntineoplastic agentCyclosporineMycophenolate mofetilSteroidAcute ieukemiaAcute iymphoblastic leukemiaAcute myeloid leukemiaAdultAplastic anemiaArticleAtaxia telangiectasiaB cell ieukemiaBurkitt ieukemiaBurkitt ieukemiaBurkitt iymphomaCancer chemotherapyCancer combination chemotherapyCancer diagnosisChildChildhood cancerClinical featureCongenital amegakaryocytic thrombocytopeniaDisease predispositionEndotracheal intubationEpilepsyFebrile neutropeniaFrontal lobeHematologic malignancyHematologyHemophagocytic syndromeHumanHypertensionHypocalcemiaHypokalemiaHypomagnesemiaInappropriate vasopressin secretionInfectionIntensive careLeukemiaMajor clinical studyMulticenter study (topic)Nuclear magnetic resonance imagingOccipital lobeOncologyParietal lobePediatric wardPosterior reversible encephalopathy syndromeRetrospective studyRisk factorT cell leukemiaThalassemia majorTumor lysis syndromeAdolescentClinical trialComplicationDiagnostic imagingFemaleHematologic diseaseLeukemiaMaleMetabolic disorderMulticenter studyPosterior reversible encephalopathy syndrome1536-3678